Skip to main content

Table 3 Efficacy and safety data from the two trials comparing apixaban with the European enoxaparin dose as thromboprophylaxis following elective total hip or knee replacement surgery [25, 26]

From: Preoperative versus postoperative initiation of thromboprophylaxis following major orthopedic surgery: safety and efficacy of postoperative administration supported by recent trials of new oral anticoagulants

  2.5 mg apixaban initiated post-surgery 40 mg enoxaparin initiated 12 h pre-surgery
ADVANCE-2 trial (knee replacement)
Total VTE and all-cause mortality (primary efficacy end-point) 147/976 (15.1%) 243/997 (24.4%)
Major bleeding 9/1501 (0.6%) 14/1508 (0.9%)
ADVANCE-3 trial (hip replacement)
Total VTE and all-cause mortality (primary efficacy end-point) 27/1949 (1.4%) 74/1917 (3.9%)
Major bleeding 22/2673 (0.8%) 18/2659 (0.7%)
  1. VTE venous thromboembolism